AKT1 and neoplasm: This finding indicates that it is necessary to maintain plasma concentrations of Akt and MEK inhibitors to significantly suppress ERK1/2 and Akt activation in tumor tissues; therefore, we will investigate the in vivo pharmacokinetic and pharmacodynamics profiles of perifosine, trametinib or PD0325901 alone and their combined treatment.